Navigation Links
Cell Therapeutics Commits to PhRMA's Code on Interactions With Healthcare Professionals
Date:12/22/2009

and breast cancer. Although they are sufficiently effective to be used as first-line (initial) treatment, they cause cumulative heart damage that may result in congestive heart failure many years later. As a result, there is a lifetime limit of anthracycline doses and most patients who previously have been treated with an anthracycline are not able to receive further anthracycline treatment if their disease returns. Pixantrone also can be administered through a peripheral vein rather than a central implanted catheter as required for other drugs in this class.

The PIX 301 EXTEND phase III clinical trial in relapsed or refractory aggressive NHL was a single-agent trial of pixantrone in patients who received two or more prior therapies and who were sensitive to treatment with anthracyclines. The results of the trial showed that patients randomized to treatment with pixantrone achieved a significantly higher rate of confirmed and unconfirmed complete response, had a significantly increased overall response rate and experience a significant improvement in median progression free survival compared to patients treated with standard chemotherapy. The most common (incidence greater than or equal to 10%) grade 3-4 adverse events reported for pixantrone-treated subjects across the studies were neutropenia and leucopenia.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.CellTherapeutics.com.

Sign up for email alerts and get RSS feeds at our Web site,

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement
2. Dennis Winger Joins Nektar Therapeutics Board of Directors
3. Northwest Biotherapeutics Announces Appointment of Robert A. Farmer to the Board of Directors
4. Oxford BioTherapeutics Appoints Michael Moore as Chairman
5. Stemline Therapeutics Announces Poster Presenting in vivo and Anti-Cancer Stem Cell Activity of SL-401 against Chronic Myeloid Leukemia (CML) at the 51st Annual Meeting of the American Society of Hematology (ASH)
6. Cell Therapeutics, Inc. (CTI) to Present at 21st Annual Piper Jaffray Health Care Conference
7. Pearl Therapeutics Appoints Howie Rosen to Board of Directors
8. Cornerstone Therapeutics to Present at the 21st Annual Piper Jaffray Health Care Conference
9. Cell Therapeutics Wins Federal Appeal to Pursue $22.8 Million Claim Against The Lash Group
10. Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML)
11. Hollis-Eden Presents New Interim Data From Prostate Cancer Phase I/II Clinical Studies of Apoptone (HE3235) at AACR Molecular Targets and Cancer Therapeutics Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Diego, CA (PRWEB) October 22, 2014 ... balances from Sartorius, A & D Weighing, Rice ... Sartorius CPA Semi-Micro Balance . The Sartorius CPA ... for an affordable high-quality, precise, and user-friendly laboratory ... manufacturing of laboratory equipment, their laboratory balances are ...
(Date:10/22/2014)... Hill, SC (PRWEB) October 22, 2014 ... expansion of its cardiovascular pharmacogenetics menu, which enables ... patient outcomes. With PCLS’s evidence-based results, healthcare ... needs and optimize their therapy, while minimizing risks ... In the U.S., according to the FDA [1] ...
(Date:10/22/2014)... --  Synthetic Biologics, Inc. (NYSE MKT: SYN), a ... and diseases, announced today that the U.S. Patent and ... a composition of matter patent application that covers the ... This is Synthetic Biologics, first allowed patent application directly ... the Company,s extensive C. difficile patent estate. ...
(Date:10/22/2014)... , Oct. 22, 2014 Nuvilex, Inc. ... approximately 400 million people worldwide are living with diabetes, ... people by 2030.  The global market for diabetes treatments ... approximately 330,000 people worldwide died from pancreatic cancer.  Pancreatic ... due to cancer in the United States ...
Breaking Biology Technology:Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 3PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2
... consecutive year, the City of Madison received recognition ... in the country. , ,In its 2006 Digital Survey ... research and advisory institute on information technology and best practices ... top user of technology in its 125,000-249,999 population category. Madison ...
... Wauwatosa, Wis. - A Medical College of Wisconsin ... work to isolate, grow, and identify a new type of ... to have the potential for diversification. , ,The readily-available adult ... , ,According to the Medical College, the team recently ...
... symposium presented last week at the Milwaukee School ... impressive as their messages. , ,Mary Glass of ... is championing the issue for Milwaukee neighborhoods, delivered a ... everyone the critical opportunity to take advantage of what ...
Cached Biology Technology:Medical College team seeks stem cell patent 2Medical College team seeks stem cell patent 3Handicapping Milwaukee's wireless initiative 2Handicapping Milwaukee's wireless initiative 3Handicapping Milwaukee's wireless initiative 4Handicapping Milwaukee's wireless initiative 5
(Date:10/15/2014)... to bacterial pneumonia in female mice to an enzyme ... are naturally more resistant to respiratory infections than males. ... increased resistance to bacterial pneumonia in female mice is ... They also show that this enzyme is ultimately activated ... , The team, lead by Professor Lester Kobzik at ...
(Date:10/15/2014)... , Oct. 15, 2014   Neurotechnology , ... announced the availability of the VeriLook Surveillance ... 3.0 provides real-time biometric face identification using live ... surveillance cameras. The new version not only identifies ... people from objects while they are moving through ...
(Date:10/14/2014)... 14, 2014)—It,s been millions of years since T. ... led by Ohio University scientists is breathing life back ... through dinosaur snouts. The research has important implications for ... but to enhance the sense of smell and cool ... said Ohio University doctoral student Jason Bourke, lead author ...
Breaking Biology News(10 mins):VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 2VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 3Dinosaur breathing study shows that noses enhanced smelling and cooled brain 2Dinosaur breathing study shows that noses enhanced smelling and cooled brain 3
... College students often spend their free time thinking about ... taking it to the next level. They,re using genetic ... in wine that,s been shown to reduce cancer and ... be entered in the International Genetically Engineered Machine (iGEM) ...
... Infectious Diseases (NAID), one of the National Institutes of ... Washington (UW) to use systems biology approaches to comprehensively ... networks that are induced or altered during the course ... program will be led by Dr. Michael Katze, UW ...
... October 16, 2008 Two new articles examine the ... health disparities. The studies, published in American Journal ... of hypertension and cardiovascular disease present in African Americans ... that these low birth weights may be a result ...
Cached Biology News:Better beer: College team creating anticancer brew 2Better beer: College team creating anticancer brew 3NIAID funds studies of how SARS and bird flu evade antiviral responses 2Racial disparities in cardiovascular health linked to birth weight, slavery 2Racial disparities in cardiovascular health linked to birth weight, slavery 3
... SYBR Safe DNA gel stain was developed ... than ethidium bromide for staining DNA in agarose ... only less mutagenic than ethidium bromide but SYBR ... of ethidium bromide. SYBR Safe stain comes as ...
... Service enables scientists who do not have access ... to have their biological samples tested for the ... easy as 1-2-3 Chose the analytes ... from the S&S antibody menu. Send your ...
... I nucleic acid gel stain is an ... bright fluorescence when bound to dsDNA and low ... dsDNA in gels using laser scanners or standard ... has also found uses in capillary electrophoresis, real-time ...
... stain has bright fluorescence when bound to dsDNA ... for detecting dsDNA in gels using laser scanners ... nucleic gel acid stain has also found ... bandshift assays. One mL stains 100 minigels. A ...
Biology Products: